Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan. Issue 6 (5th February 2020)

• Record Type: Journal Article
• Authors: Anwari, Palwasha; Debellut, Frédéric; Vodicka, Elisabeth; Clark, Andrew; Farewar, Farhad; Zhwak, Zubiada A.; Nazary, Dastagger; Pecenka, Clint; Scott LaMontagne, D.; Safi, Najibullah
• Is Part Of: Vaccine. Volume 38:Issue 6(2020)
• Page Start: 1352
• Page End: 1362
• Publication Date: 2020-02-05
• Subjects: Human papillomavirus -- HPV vaccine -- Cervical cancer -- Cost-effectiveness analysis -- Afghanistan; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.12.013
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Introduction: Human papillomavirus (HPV) vaccination has not been introduced in many countries in South-Central Asia, including Afghanistan, despite the sub-region having the highest incidence rate of cervical cancer in Asia. This study estimates the potential health impact and cost-effectiveness of HPV vaccination in Afghanistan to inform national decision-making. Method: An Excel-based static cohort model was used to estimate the lifetime costs and health outcomes of vaccinating a single cohort of 9-year-old girls in the year 2018 with the bivalent HPV vaccine, compared to no vaccination. We also explored a scenario with a catch-up campaign for girls aged 10–14 years. Input parameters were based on local sources, published literature, or assumptions when no data was available. The primary outcome measure was the discounted cost per disability-adjusted life-year (DALY) averted, evaluated from both government and societal perspectives. Results: Vaccinating a single cohort of 9-year-old girls against HPV in Afghanistan could avert 1718 cervical cancer cases, 125 hospitalizations, and 1612 deaths over the lifetime of the cohort. The incremental cost-effectiveness ratio was US$426 per DALY averted from the government perspective and US$400 per DALY averted from the societal perspective. The estimated annual cost of the HPV vaccination program (US$3, 343, 311) represents approximately 3.53% of the country′s total immunization budget for 2018 or 0.13% of total health expenditures. Conclusion: In Afghanistan, HPV vaccine introduction targeting a single cohort is potentially cost-effective (0.7 times the GDP per capita of $586) from both the government and societal perspective with additional health benefits generated by a catch-up campaign, depending on the government′s willingness to pay for the projected health outcomes.